NASDAQ:MIRA
Mira Pharmaceuticals, Inc.
Mira Pharmaceuticals, Inc. reported net income of −$10.4M in fiscal 2025.Summary generated from Mira Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−165.9%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count changen/a
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a |
| Operating income | n/a | n/a | n/a | n/a |
| Net income | −7 | −12 | −8 | −10 |
| Free cash flow | n/a | n/a | n/a | n/a |
Recent filings
- 8-KRegulation FD disclosure
Sep 17, 2026 - 8-KResults of a shareholder vote
Sep 16, 2026 - 8-KRegulation FD disclosure
Sep 1, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KRegulation FD disclosure
Aug 6, 2026 - 8-KNotice of delisting or listing-rule failure
Jul 31, 2026 - DEF 14AProxy statement
Jul 28, 2026 - 8-KRegulation FD disclosure
Jul 10, 2026